Pharmacogenomics Market by Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others), Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others), and End User (Hospitals & Clinics, Research Institutions and Academic Institutes and Others): Analysis and Industry Forecast, 2027
The pharmacogenomics market refers to the market for diagnostic tests and technologies used to study an individual's genetic makeup and how it affects their response to medications. Pharmacogenomics combines the fields of pharmacology (the study of drugs) and genomics (the study of genes and their functions). Pharmacogenomics Market is likely to grow at a rate of 9.62% CAGR by 2027.
Pharmacogenomic testing analyzes an individual's genetic variations to predict their response to specific medications. It helps healthcare professionals personalize treatment plans, optimize drug selection and dosing, and reduce the risk of adverse drug reactions. By understanding how an individual's genes influence drug metabolism, efficacy, and safety, pharmacogenomics aims to improve medication outcomes and enhance patient care.
Pharmacogenomics market by Technology
Next Generation Sequencing
Polymerase Chain Reaction
Gel electrophoresis
Mass Spectrometry
Microarray
Pharmacogenomics market by Application
Cardiovascular disease
Infectious diseases
Oncology
Neurological diseases
Psychiatry
Pharmacogenomics market by End User
Hospitals and clinics
Research institutions
Academic institute
Pharmacogenomics Market by Geography
North America
Europe
Asia Pacific
Rest of the World
As per the technology, the market is segmented into polymerase chain reaction, sequencing, microarray, mass spectrometry, and electrophoresis. Polymerase chain reaction has the highest market share in the technology segment. Owing to its irreplaceability in terms of use for the amplification of a small segment of DNA, polymerase chain reaction is projected to continue its trend throughout the estimated period.
As per the application, the market is classified as oncology, cardiovascular disease, neurological disease, infectious diseases, psychiatry, and pain management amongst other applications. The oncology has the maximum market share in the application segment. This is ascribed to the rise in prevalence of cancer across the world and surge in demand for personalized therapy.
As per the end user, it is divided into hospitals and clinics, research organizations & academic institutes. The hospitals and clinics segment has the significant share. This is ascribed to the fact that hospitals are well-equipped with molecular diagnostic lab units to serve the various requirements of the patients.
The pharmacogenomics market has been growing rapidly in recent years due to several factors. These include advancements in genetic testing technologies, increasing awareness among healthcare professionals and patients, the rising demand for personalized medicine, and the decreasing cost of genetic testing. Additionally, regulatory agencies and healthcare organizations are increasingly recognizing the importance of integrating pharmacogenomic information into clinical practice.
Key players in the pharmacogenomics market include diagnostic companies, pharmaceutical companies, and research institutions. These entities develop and market pharmacogenomic testing products, including genotyping assays, sequencing technologies, and software solutions for data analysis and interpretation.
The market encompasses a wide range of applications, including oncology, cardiology, psychiatry, infectious diseases, and other therapeutic areas. Pharmacogenomic testing is particularly valuable for medications with a narrow therapeutic index, drugs that require dose adjustment, and those known to have significant interindividual variability in response.
Government initiatives, research collaborations, and reimbursement policies also influence the growth of the pharmacogenomics market. Some countries and healthcare systems have started implementing pharmacogenomic testing programs or guidelines to improve patient care and medication safety.
As the field of pharmacogenomics continues to evolve, there are ongoing efforts to expand the knowledge base of gene-drug interactions, develop standardized guidelines for clinical implementation, and enhance the accessibility and affordability of pharmacogenomic testing.
It's important to note that my knowledge is based on information available up until September 2021, and there may have been new developments or changes in the pharmacogenomics market since then. For the most up-to-date and accurate information, it is recommended to refer to industry reports, market research studies, and consult with healthcare professionals or experts in the field
The major leading companies of the pharmacogenomics market are Abbott Laboratories, Becton, Dickinson And Company, Biomerieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Perkinelmer Inc., Siemens Ag, Thermo Fisher Scientific, Inc., and Tosoh Corporation
For the most up-to-date information on the current state of the pharmacogenomics market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. A complete analysis of all major geographical regions is included in the report which determines the possible opportunities in these regions.
Detailed information about the attributes which are generating growth in the pharmacogenomics market in the forecast period.
An exact estimation of the pharmacogenomics market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
Pharmacogenomic testing analyzes an individual's genetic variations to predict their response to specific medications. It helps healthcare professionals personalize treatment plans, optimize drug selection and dosing, and reduce the risk of adverse drug reactions. By understanding how an individual's genes influence drug metabolism, efficacy, and safety, pharmacogenomics aims to improve medication outcomes and enhance patient care.
Pharmacogenomics market by Technology
Next Generation Sequencing
Polymerase Chain Reaction
Gel electrophoresis
Mass Spectrometry
Microarray
Pharmacogenomics market by Application
Cardiovascular disease
Infectious diseases
Oncology
Neurological diseases
Psychiatry
Pharmacogenomics market by End User
Hospitals and clinics
Research institutions
Academic institute
Pharmacogenomics Market by Geography
North America
Europe
Asia Pacific
Rest of the World
As per the technology, the market is segmented into polymerase chain reaction, sequencing, microarray, mass spectrometry, and electrophoresis. Polymerase chain reaction has the highest market share in the technology segment. Owing to its irreplaceability in terms of use for the amplification of a small segment of DNA, polymerase chain reaction is projected to continue its trend throughout the estimated period.
As per the application, the market is classified as oncology, cardiovascular disease, neurological disease, infectious diseases, psychiatry, and pain management amongst other applications. The oncology has the maximum market share in the application segment. This is ascribed to the rise in prevalence of cancer across the world and surge in demand for personalized therapy.
As per the end user, it is divided into hospitals and clinics, research organizations & academic institutes. The hospitals and clinics segment has the significant share. This is ascribed to the fact that hospitals are well-equipped with molecular diagnostic lab units to serve the various requirements of the patients.
The pharmacogenomics market has been growing rapidly in recent years due to several factors. These include advancements in genetic testing technologies, increasing awareness among healthcare professionals and patients, the rising demand for personalized medicine, and the decreasing cost of genetic testing. Additionally, regulatory agencies and healthcare organizations are increasingly recognizing the importance of integrating pharmacogenomic information into clinical practice.
Key players in the pharmacogenomics market include diagnostic companies, pharmaceutical companies, and research institutions. These entities develop and market pharmacogenomic testing products, including genotyping assays, sequencing technologies, and software solutions for data analysis and interpretation.
The market encompasses a wide range of applications, including oncology, cardiology, psychiatry, infectious diseases, and other therapeutic areas. Pharmacogenomic testing is particularly valuable for medications with a narrow therapeutic index, drugs that require dose adjustment, and those known to have significant interindividual variability in response.
Government initiatives, research collaborations, and reimbursement policies also influence the growth of the pharmacogenomics market. Some countries and healthcare systems have started implementing pharmacogenomic testing programs or guidelines to improve patient care and medication safety.
As the field of pharmacogenomics continues to evolve, there are ongoing efforts to expand the knowledge base of gene-drug interactions, develop standardized guidelines for clinical implementation, and enhance the accessibility and affordability of pharmacogenomic testing.
It's important to note that my knowledge is based on information available up until September 2021, and there may have been new developments or changes in the pharmacogenomics market since then. For the most up-to-date and accurate information, it is recommended to refer to industry reports, market research studies, and consult with healthcare professionals or experts in the field
The major leading companies of the pharmacogenomics market are Abbott Laboratories, Becton, Dickinson And Company, Biomerieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Perkinelmer Inc., Siemens Ag, Thermo Fisher Scientific, Inc., and Tosoh Corporation
For the most up-to-date information on the current state of the pharmacogenomics market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. A complete analysis of all major geographical regions is included in the report which determines the possible opportunities in these regions.
Detailed information about the attributes which are generating growth in the pharmacogenomics market in the forecast period.
An exact estimation of the pharmacogenomics market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TECHNOLOGY: MARKET SIZE & ANALYSIS
5.1. Next Generation Sequencing
5.2. Polymerase Chain Reaction
5.3. Gel electrophoresis
5.4. Mass Spectrometry
5.5. Microarray
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Cardiovascular disease
6.2. Infectious diseases
6.3. Oncology
6.4. Neurological diseases
6.5. Psychiatry
7. END USER: MARKET SIZE & ANALYSIS
7.1. Hospitals and clinics
7.2. Research institutions
7.3. Academic institutes
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. MYRIAD GENETICS INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. DYNAMIC DNA LABORATORIES
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. OPKO HEALTH, INC
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. ONEOME, LLC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. EMPIRE GENOMICS, LLC
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. ADMERA HEALTH.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. ILLUMINA, INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. THERMO FISHER SCIENTIFIC, INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. F. HOFFMANN-LA ROCHE LTD
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. ABBOTT LABORATORIES
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TECHNOLOGY: MARKET SIZE & ANALYSIS
5.1. Next Generation Sequencing
5.2. Polymerase Chain Reaction
5.3. Gel electrophoresis
5.4. Mass Spectrometry
5.5. Microarray
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Cardiovascular disease
6.2. Infectious diseases
6.3. Oncology
6.4. Neurological diseases
6.5. Psychiatry
7. END USER: MARKET SIZE & ANALYSIS
7.1. Hospitals and clinics
7.2. Research institutions
7.3. Academic institutes
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. MYRIAD GENETICS INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. DYNAMIC DNA LABORATORIES
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. OPKO HEALTH, INC
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. ONEOME, LLC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. EMPIRE GENOMICS, LLC
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. ADMERA HEALTH.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. ILLUMINA, INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. THERMO FISHER SCIENTIFIC, INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. F. HOFFMANN-LA ROCHE LTD
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. ABBOTT LABORATORIES
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR NEXT GENERATION SEQUENCING, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR POLYMERASE CHAIN REACTION,BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR GEL ELECTROPHORESIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR MASS SPECTROMETRY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR MICROARRAY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR CARDIOVASCULAR DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR NEUROLOGICAL DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR PSYCHIATRY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR HOSPITALS AND CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR RESEARCH INSTITUTIONS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR ACADEMIC INSTITUTES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 18. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 19. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 20. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 21. U.S PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 22. U.S PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 23. U.S PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 24. CANADAPHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 25. CANADA PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. CANADA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 27. EUROPE PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 28. EUROPE PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 29. EUROPEPHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. EUROPE PHARMACOGENOMICS MARKETVALUE, END USER,2021-2027 (USD BILLION)
TABLE 31. GERMANY PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 32. GERMANY PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 33. GERMANY PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 34. U.K PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 35. U.K PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. U.K PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 37. FRANCE PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY2021-2027 (USD BILLION)
TABLE 38. FRANCE PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 39. FRANCE PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 40. ITALY PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 41. ITALY PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 42. ITALY PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 43. SPAIN PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 44. SPAIN PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 45. SPAIN PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 46. ROE PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 47. ROE PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 48. ROE PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 50. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 51. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 52. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 53. CHINA PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 54. CHINA PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 55. CHINA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 56. INDIA PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 57. INDIA PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 58. INDIA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 59. JAPAN PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 60. JAPAN PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 61. JAPAN PHARMACOGENOMICS MARKETVALUE, BY END USER2021-2027 (USD BILLION)
TABLE 62. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 63. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 64. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 65. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 66. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 67. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 68. MYRIAD GENETICS INC: FINANCIALS
TABLE 69. MYRIAD GENETICS INC: PRODUCTS & SERVICES
TABLE 70. MYRIAD GENETICS INC: RECENT DEVELOPMENTS
TABLE 71. DYNAMIC DNA LABORATORIES: FINANCIALS
TABLE 72. DYNAMIC DNA LABORATORIES: PRODUCTS & SERVICES
TABLE 73. DYNAMIC DNA LABORATORIES: RECENT DEVELOPMENTS
TABLE 74. OPKO HEALTH, INC.: FINANCIALS
TABLE 75. OPKO HEALTH, INC.: PRODUCTS & SERVICES
TABLE 76. OPKO HEALTH, INC.: RECENT DEVELOPMENTS
TABLE 77. ONEOME, LLC: FINANCIALS
TABLE 78. ONEOME, LLC: PRODUCTS & SERVICES
TABLE 79. ONEOME, LLC: RECENT DEVELOPMENTS
TABLE 80. EMPIRE GENOMICS, LLC: FINANCIALS
TABLE 81. EMPIRE GENOMICS, LLC: PRODUCTS & SERVICES
TABLE 82. EMPIRE GENOMICS, LLC: RECENT DEVELOPMENTS
TABLE 83. ADMERA HEALTH.: FINANCIALS
TABLE 84. ADMERA HEALTH: PRODUCTS & SERVICES
TABLE 85. ADMERA HEALTH: RECENT DEVELOPMENTS
TABLE 86. ILLUMINA, INC: FINANCIALS
TABLE 87. ILLUMINA, INC: PRODUCTS & SERVICES
TABLE 88. ILLUMINA, INC: RECENT DEVELOPMENTS
TABLE 89. THERMO FISHER SCIENTIFIC, IN: FINANCIALS
TABLE 90. THERMO FISHER SCIENTIFIC, IN: PRODUCTS & SERVICES
TABLE 91. THERMO FISHER SCIENTIFIC, IN: RECENT DEVELOPMENTS
TABLE 92. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 93. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 94. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 95. ABBOTT LABORATORIES: FINANCIALS
TABLE 96. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 97. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 1. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR NEXT GENERATION SEQUENCING, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR POLYMERASE CHAIN REACTION,BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR GEL ELECTROPHORESIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR MASS SPECTROMETRY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR MICROARRAY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR CARDIOVASCULAR DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR NEUROLOGICAL DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR PSYCHIATRY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR HOSPITALS AND CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR RESEARCH INSTITUTIONS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET VALUE FOR ACADEMIC INSTITUTES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 18. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 19. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 20. NORTH AMERICA PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 21. U.S PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 22. U.S PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 23. U.S PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 24. CANADAPHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 25. CANADA PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. CANADA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 27. EUROPE PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 28. EUROPE PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 29. EUROPEPHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. EUROPE PHARMACOGENOMICS MARKETVALUE, END USER,2021-2027 (USD BILLION)
TABLE 31. GERMANY PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 32. GERMANY PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 33. GERMANY PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 34. U.K PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 35. U.K PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. U.K PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 37. FRANCE PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY2021-2027 (USD BILLION)
TABLE 38. FRANCE PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 39. FRANCE PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 40. ITALY PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 41. ITALY PHARMACOGENOMICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 42. ITALY PHARMACOGENOMICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 43. SPAIN PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 44. SPAIN PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 45. SPAIN PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 46. ROE PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 47. ROE PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 48. ROE PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC PHARMACOGENOMICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 50. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 51. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 52. ASIA PACIFC PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 53. CHINA PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 54. CHINA PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 55. CHINA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 56. INDIA PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 57. INDIA PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 58. INDIA PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 59. JAPAN PHARMACOGENOMICS MARKET VALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 60. JAPAN PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 61. JAPAN PHARMACOGENOMICS MARKETVALUE, BY END USER2021-2027 (USD BILLION)
TABLE 62. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 63. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 64. REST OF APAC PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 65. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY TECHNOLOGY, 2021-2027 (USD BILLION)
TABLE 66. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 67. REST OF WORLD PHARMACOGENOMICS MARKETVALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 68. MYRIAD GENETICS INC: FINANCIALS
TABLE 69. MYRIAD GENETICS INC: PRODUCTS & SERVICES
TABLE 70. MYRIAD GENETICS INC: RECENT DEVELOPMENTS
TABLE 71. DYNAMIC DNA LABORATORIES: FINANCIALS
TABLE 72. DYNAMIC DNA LABORATORIES: PRODUCTS & SERVICES
TABLE 73. DYNAMIC DNA LABORATORIES: RECENT DEVELOPMENTS
TABLE 74. OPKO HEALTH, INC.: FINANCIALS
TABLE 75. OPKO HEALTH, INC.: PRODUCTS & SERVICES
TABLE 76. OPKO HEALTH, INC.: RECENT DEVELOPMENTS
TABLE 77. ONEOME, LLC: FINANCIALS
TABLE 78. ONEOME, LLC: PRODUCTS & SERVICES
TABLE 79. ONEOME, LLC: RECENT DEVELOPMENTS
TABLE 80. EMPIRE GENOMICS, LLC: FINANCIALS
TABLE 81. EMPIRE GENOMICS, LLC: PRODUCTS & SERVICES
TABLE 82. EMPIRE GENOMICS, LLC: RECENT DEVELOPMENTS
TABLE 83. ADMERA HEALTH.: FINANCIALS
TABLE 84. ADMERA HEALTH: PRODUCTS & SERVICES
TABLE 85. ADMERA HEALTH: RECENT DEVELOPMENTS
TABLE 86. ILLUMINA, INC: FINANCIALS
TABLE 87. ILLUMINA, INC: PRODUCTS & SERVICES
TABLE 88. ILLUMINA, INC: RECENT DEVELOPMENTS
TABLE 89. THERMO FISHER SCIENTIFIC, IN: FINANCIALS
TABLE 90. THERMO FISHER SCIENTIFIC, IN: PRODUCTS & SERVICES
TABLE 91. THERMO FISHER SCIENTIFIC, IN: RECENT DEVELOPMENTS
TABLE 92. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 93. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 94. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 95. ABBOTT LABORATORIES: FINANCIALS
TABLE 96. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 97. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
